Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.…
Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck
Qiagen (NYSE: QGEN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 5,400 employees.
The shares were at 49.30 USD on 20 November 2026, up 12.0% over 52 weeks. Its 52-week range is 32.53 USD to 57.82 USD: the price is 14.7% below the high and 51.6% above the low.
At a market capitalisation of 10.18B USD, it trades at 26.6 times trailing earnings and 18.5 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.6, a discount of 23% for QGEN. It pays a dividend yielding 0.71% (it pays out 19% of its earnings), against a median of 0.77% among the dividend payers in that peer group.
Qiagen reports return on equity of 11.2%, an operating margin of 26.7% and revenue up 2.9% year over year.
Its debt exceeds its cash by 815.48M USD, a debt-to-equity ratio of 0.48. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Hold; their mean price target of 49.77 USD is 1.0% above the current price. The next earnings report is expected on 3 February 2027.